Saturday, August 9, 2025, marked one year since the approval of neffy, the first needle-free treatment for severe allergic reactions.
HCPLive spoke with numerous experts on the impact of a needle-free epinephrine option for severe allergic reactions. This feature includes the perspectives of:
- Matthew Greenhawt, MD, MBA, MSc: CMO of Asthma and Allergy Foundation of America (AAFA)
- Brian Schroer, MD: Allergist immunologist at the Cleveland Clinic Children’s Hospital
- Colleen Kraft, MD, MBA: Clinical professor of Pediatrics at the Keck School of Medicine of USC and an attending physician at the Children’s Hospital Los Angeles
- Ryan Haumschild, PharmD, MS, MBA: Vice President of Pharmacy at Emory Healthcare and Winship Cancer Institute
- Thomas Casale, MD: Professor of Medicine at University of South Florida in Tampa
Source: 1 Year Since the FDA Approved Epinephrine Nasal Spray — HCPLive
Note of Disclosure: ARS Pharma — the company that developed and commercializes neffy — is an advertiser with SnackSafely.com.
